Moderna stock price forecast sees technical support at the $92 level, backed by increased institutional buying. MACD cross-over last week indicates early-stage bullish momentum, which could carry prices toward $106 in the next 30 trading sessions. We can see that Moderna does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Moderna, (below). Of course, keep in mind that there are other factors to consider, too. So, this combination indicates that Moderna will most likely beat the consensus EPS estimate. Near-term Moderna stock price forecast indicates consolidation around $95–$100, as investors monitor regulatory updates. Strong cash reserves of $13B provide capital flexibility for R&D, which could lift valuations by 8–12% in bullish scenarios.